A 24-week, parallel-group, open-label, randomized clinical trial comparing the early antiviral efficacy of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive chronic hepatitis B virus infection in adult Chinese patients

Clinical Therapeutics

Volumn 32, Issue 4, 2010, Pages 649-658

  Zheng, Ming Hua ^a   Shi, Ke Qing ^a   Dai, Zhi Juan ^a   Ye, Chao ^a   Chen, Yong Ping ^a  

^a THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Entecavir; HBeAg; HBV; Hepatitis B; Seroconversion; Telbivudine

Indexed keywords

ALANINE AMINOTRANSFERASE; CREATINE KINASE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; TELBIVUDINE; VIRUS DNA;

ADULT; ARTICLE; BLOOD SAMPLING; CHINESE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEMOGRAPHY; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEMALE; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PARALLEL DESIGN; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; CHINA; DNA, VIRAL; FEMALE; GUANINE; HEPATITIS B; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; MALE; NUCLEOSIDES; PYRIMIDINONES;

EID: 77952484856     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2010.04.001     Document Type: Article

References (32)

1. Lok AS, McMahon BJ Chronic hepatitis B. Hepatology 2007, 45:507-539.
2. Hepatitis B vaccines [in English and French]. Wkly Epidemiol Rec. 2004, 79:255-263.
3. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006, 295:65-73. for the REVEAL-HBV Study Group.
4. Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006, 130:678-686. for the Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer-In HBV (the REVEAL-HBV) Study Group.
5. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis and advanced liver disease. N Engl J Med 2004, 351:1521-1531. for the Cirrhosis Asian Lamivudine Multicentre Study Group.
6. Yuen MF, Seto WK, Chow DH, et al. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Antivir Ther 2007, 12:1295-1303.
7. Paik YH, Han KH, Hong SP, et al. The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B. Antivir Ther 2006, 11:447-455.
8. Yeon JE, Yoo W, Hong SP, et al. Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil. Gut 2006, 55:1488-1495.
9. Tenney DJ, Rose RE, Baldick CJ, et al. Two-year assessment of entecavir resistance in lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother 2007, 51:902-911.
10. Goulis I, Dalekos GN Entecavir monotherapy for lamivudine-refractory chronic hepatitis B. Expert Rev Anti Infect Ther 2008, 6:855-859.
11. Kurashige N, Hiramatsu N, Ohkawa K, et al. Initial viral response is the most powerful predictor of the emergence of YMDD mutant virus in chronic hepatitis B patients treated with lamivudine. Hepatol Res 2008, 38:450-456.
12. Kau A, Vermehren J, Sarrazin C Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol 2008, 49:634-651.
13. Nguyen MH, Keeffe EB Chronic hepatitis B: Early viral suppression and long-term outcomes of therapy with oral nucleos(t)ides. J Viral Hepat 2009, 16:149-155.
14. Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAG-positive chronic hepatitis B. N Engl J Med 2006, 354:1001-1010. for the BEHoLD AI463022 Study Group.
15. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAG-negative chronic hepatitis B [published correction appears in N Engl J Med. 2006;354:1863]. N Engl J Med 2006, 354:1011-1020. for the BEHoLD AI463027 Study Group.
16. Chan HL, Heathcote EJ, Marcellin P, et al. Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: A randomized trial. Ann Intern Med 2007, 147:745-754. for the 018 Study Group.
17. Matthews SJ Telbivudine for the management of chronic hepatitis B virus infection. Clin Ther 2007, 29:2635-2653.
18. Shamliyan TA, MacDonald R, Shaukat A, et al. Antiviral therapy for adults with chronic hepatitis B: A systematic review for a National Institutes of Health Consensus Development Conference. Ann Intern Med 2009, 150:111-124.
19. Leung N, Peng CY, Hann HW, et al. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir. Hepatology 2009, 49:72-79.
20. Mihm U, Chan HL, Zeuzem S, et al. Virodynamic predictors of response to pegylated interferon and lamivudine combination treatment of hepatitis B e antigen-positive chronic hepatitis B. Antivir Ther 2008, 13:1029-1037.
21. Moher D, Schulz KF, Altman DG The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 2001, 357:1191-1194.
22. Wilkinson JH, Baron DN, Moss DW, et al. Standardization of clinical enzyme assays: A reference method for aspartate and alanine transaminases. J Clin Pathol 1972, 25:940-944.
23. Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007, 357:2576-2588. for the Globe Study Group.
24. Eng J. Sample size estimation: How many individuals should be studied?. Radiology 2003, 227:309-313.
25. Sempos CT, Picciano MF The intention to treat principle, and the potential impact of excluding data from the analysis of clinical trial data. J Nutr. 2009, 139:1204. author reply 1205-1206.
26. Keeffe EB, Zeuzem S, Koff RS, et al. Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol 2007, 5:890-897.
27. Hou J, Yin YK, Xu D, et al. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial. Hepatology 2008, 47:447-454.
28. Tillmann HL, McHutchison JG Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2008, 358:1517. author reply 1517-1518.
29. Yao GB, Zhu M, Wang YM, et al. A double-blind, double-dummy, randomized, controlled study of entecavir versus lamivudine for treatment of chronic hepatitis B [in Chinese]. Zhonghua Nei Ke Za Zhi 2006, 45:891-895.
30. Yao G Entecavir is a potent anti-HBV drug superior to lamivudine: Experience from clinical trials in China. J Antimicrob Chemother 2007, 60:201-205.
31. DiBisceglie AM, Lai CL, Gane E, et al. Telbivudine GLOBE trial: Maximal early HBV suppression is predictive of optimal two-year efficacy in nucleoside treated hepatitis B patients. Hepatology 2006, 44(Suppl 1):230A.
32. Liaw YF On-treatment outcome prediction and adjustment during chronic hepatitis B therapy: Now and future. Antivir Ther 2009, 14:13-22.